Salinas Sánchez A S, Moreno Avilés J, Pérez Albacete M, Salmerón Lopez-Rua J, Guardiola Más A, Server Falgas G
Actas Urol Esp. 1989 Mar-Apr;13(2):99-102.
We present a comparative study of the evolution of 250 patients with primary surface tumour, analysing the percentages of relapses and period free of illness according to the type of endovesical chemoprophylactic treatment administered. In 103 cases no chemotherapy treatment at all was administered, whilst in 90 cases thiotepa was applied and in 57 adriamycin. We have studied the evolution of these patients in accordance with the number of tumours, location, cell grade and stage, assessing the progression in grade and state of the primary tumours. After analysing the results, we observe that relapses are significantly more numerous and more precocious in patients receiving no chemotherapy treatment at all, and differences may be seen on an overall basis between adriamycin and thiotepa. In grade 1, stage 0 and single tumours, though they displayed a longer period free of illness in treated patients, the relapses were similar to those of non-treated patients. In this type of tumour thiotepa proved more effective than adriamycin, although the latter provides a longer period free of illness. Patients with high grade and stage tumours do indeed relapse significantly less and later when they receive treatment, and adriamycin achieves better results. As regards location, save in the case of tumours located on the cupula and front face, where relapses were the same between groups of treated and non-treated patients, in the rest the evolution of the tumours was better in treated patients irrespective of location.(ABSTRACT TRUNCATED AT 250 WORDS)
我们对250例原发性浅表肿瘤患者的病情演变进行了一项对比研究,根据所采用的膀胱内化学预防治疗类型分析复发率和无病期的百分比。103例患者未接受任何化疗,90例应用了噻替派,57例应用了阿霉素。我们根据肿瘤数量、位置、细胞分级和分期研究了这些患者的病情演变,评估原发性肿瘤在分级和分期方面的进展。分析结果后,我们观察到,完全未接受化疗的患者复发明显更多且更早,阿霉素和噻替派在总体上存在差异。在1级、0期和单发肿瘤患者中,尽管接受治疗的患者无病期较长,但复发情况与未治疗患者相似。在这类肿瘤中,噻替派比阿霉素更有效,尽管阿霉素的无病期更长。高级别和晚期肿瘤患者接受治疗后复发确实明显较少且较晚,阿霉素取得了更好的效果。至于肿瘤位置,除了位于穹隆部和正面的肿瘤,治疗组和未治疗组患者的复发情况相同外,其余部位的肿瘤,无论位置如何,接受治疗的患者病情演变情况更好。(摘要截选于250词)